ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 103 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,129,076 | -34.0% | 3,960,449 | -0.0% | 0.73% | -25.6% |
| Q2 2023 | $41,084,374 | +28.2% | 3,961,849 | 0.0% | 0.98% | +27.7% |
| Q1 2023 | $32,051,358 | -48.6% | 3,961,849 | +0.0% | 0.76% | -49.0% |
| Q4 2022 | $62,389,672 | +0.1% | 3,961,249 | 0.0% | 1.50% | -6.8% |
| Q3 2022 | $62,350,000 | +13.7% | 3,961,249 | +0.9% | 1.61% | +0.9% |
| Q2 2022 | $54,823,000 | -17.7% | 3,927,149 | +1.6% | 1.60% | -4.8% |
| Q1 2022 | $66,633,000 | +18.7% | 3,865,034 | +0.1% | 1.68% | +29.3% |
| Q4 2021 | $56,144,000 | -18.0% | 3,861,347 | +1.5% | 1.30% | -9.9% |
| Q3 2021 | $68,458,000 | +3.6% | 3,803,232 | +1.1% | 1.44% | +10.2% |
| Q2 2021 | $66,066,000 | -26.5% | 3,762,312 | +5.4% | 1.31% | -33.4% |
| Q1 2021 | $89,944,000 | +419.5% | 3,569,192 | +33.4% | 1.96% | +434.6% |
| Q4 2020 | $17,314,000 | +224.5% | 2,676,100 | +28.9% | 0.37% | +171.9% |
| Q3 2020 | $5,336,000 | +100.4% | 2,076,307 | +26.3% | 0.14% | +84.9% |
| Q2 2020 | $2,663,000 | +60.0% | 1,644,015 | +2.8% | 0.07% | +5.8% |
| Q1 2020 | $1,664,000 | -45.0% | 1,600,000 | 0.0% | 0.07% | -28.1% |
| Q4 2019 | $3,024,000 | -5.9% | 1,600,000 | -46.2% | 0.10% | -25.0% |
| Q3 2019 | $3,213,000 | -27.7% | 2,974,754 | +46.7% | 0.13% | -20.5% |
| Q2 2019 | $4,441,000 | -56.4% | 2,028,000 | +19.3% | 0.16% | -59.0% |
| Q1 2019 | $10,183,000 | +3.7% | 1,700,000 | +27.9% | 0.39% | -15.3% |
| Q4 2018 | $9,824,000 | -23.1% | 1,329,400 | +51.1% | 0.46% | +0.2% |
| Q3 2018 | $12,778,000 | -25.2% | 880,000 | +2.8% | 0.46% | -29.6% |
| Q2 2018 | $17,094,000 | +84.1% | 856,000 | +61.5% | 0.66% | +66.2% |
| Q1 2018 | $9,286,000 | -9.3% | 530,000 | +27.7% | 0.40% | -14.7% |
| Q4 2017 | $10,234,000 | -9.9% | 415,000 | -5.7% | 0.46% | -11.5% |
| Q3 2017 | $11,356,000 | -4.8% | 440,000 | 0.0% | 0.52% | -13.1% |
| Q2 2017 | $11,933,000 | -40.7% | 440,000 | -34.8% | 0.60% | -48.1% |
| Q1 2017 | $20,129,000 | -32.6% | 675,000 | -38.6% | 1.16% | -41.9% |
| Q4 2016 | $29,854,000 | +14.7% | 1,100,000 | +8.3% | 2.00% | +22.5% |
| Q3 2016 | $26,020,000 | +40.9% | 1,016,000 | +1.6% | 1.63% | +19.3% |
| Q2 2016 | $18,470,000 | +8.8% | 1,000,000 | +11.7% | 1.37% | -3.9% |
| Q1 2016 | $16,970,000 | -29.7% | 895,500 | -0.1% | 1.42% | -22.3% |
| Q4 2015 | $24,142,000 | – | 896,154 | – | 1.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |